Résumé
A biosynthetic gene cluster for the bioactive fungal sesterterpenoids variecolin ( 1) and variecolactone ( 2) was identified in Aspergillus aculeatus ATCC 16872. Heterologous production of 1 and 2 was achieved in Aspergillus oryzae by expressing the sesterterpene synthase VrcA and the cytochrome P450 VrcB. Intriguingly, the replacement of VrcB with homologous P450s from other fungal terpenoid pathways yielded three new variecolin analogues ( 5- 7). Analysis of the compounds' anticancer activity in vitro and in vivo revealed that although 5 and 1 had comparable activities, 5 was associated with significantly reduced toxic side effects in cancer-bearing mice, indicating its potentially broader therapeutic window. Our study describes the first tests of variecolin and its analogues in animals and demonstrates the utility of synthetic biology for creating molecules with improved biological activities.
Résumé
Although the number of sesterterpenoids is fewer than other terpenoids reported, they have presented a wide range of biological activities and medicinal value. Reported filamentous fungal sesterterpene synthases are special on bifunctional two catalytically independent domains: prenyltransferase and terpene cyclase, but less specific on substrates selection and diverse ways of cyclization. This article reviews the research advances in filamentous fungal sesterterpenoids and their synthases, especially describes filamentous fungal sesterterpenoids and the structure and function characteristics of sesterterpene synthase.